✦ LIBER ✦

Radiotherapy in advanced prostatic carcinoma

✍ Scribed by M. J. Varkarakis; J. Webster; T. Bhanalaph; G. P. Murphy

Publisher: John Wiley and Sons
Year: 1972
Tongue: English
Weight: 378 KB
Volume: 4
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.2930040514

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

External beam radiotherapy and hyperther

External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma : Results of long term follow-up

✍ Özer Algan; Helen Fosmire; K. Hynynen; Bruce Dalkin; Haitan Cui; George Drach; B 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

Radiotherapy for prostate carcinoma

✍ Kevin Leonard; John A. Stryker 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 795 KB

Adrenalectomy and hypophysectomy in adva

Adrenalectomy and hypophysectomy in advanced prostatic carcinoma

✍ Gustavo Reynoso; Gerald P. Murphy 📂 Article 📅 1972 🏛 John Wiley and Sons 🌐 English ⚖ 376 KB 👁 2 views

Hormonal Therapy for Advanced Prostatic

Hormonal Therapy for Advanced Prostatic Carcinoma

✍ Allen D. Seftel; J. Patrick Spirnak; Martin I. Resnick 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 841 KB

Since the work of Huggins and Hodges, hormonal therapy, i.e., orchiectomy or estrogens, has been the gold standard of treatment for patients with advanced adenocarcinoma of the prostate. Recently, many new drugs have been introduced in the hope of achieving a beneficial response as compared with hor

Buserelin as primary therapy in advanced

Buserelin as primary therapy in advanced prostatic carcinoma

✍ Cary A. Presant; Mark S. Soloway; Sol S. Klioze; John W. Kosola; Alun L. Yakabow 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB 👁 2 views

Antiandrogenic agents as monotherapy in

Antiandrogenic agents as monotherapy in advanced prostatic carcinoma

✍ Mark S. Soloway; Haim Matzkin 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 563 KB

Pure antiandrogens have a quality-of-life advantage over other androgen ablation methods in the treatment of patients with prostatic cancer because they do not reduce the serum testosterone and therefore do not have a marked inhibitory effect on libido and potency. The long half-life of two of the t